JP Morgan Has 5 Blue Chip Passive Income Stocks as Top Picks for May Chris Hondros / Getty Images News via Getty Images 24/7 InsightsAI stocks are facing headwinds and sky high valuations are cooling downJ.P. Morgan’s top picks are in May are stable, established brands2 legendary, high-yield dividend stocks Wall Street loves (free access)The artificial intelligence rally over the past year and a half, led by the so-called Magnificent Seven, has been remarkable if you owned those stocks. However, most of t ...

Often overlooked, especially in times of AI revolution, the healthcare market is always a safe bet for investors, as it is a multiple trillion, highly innovative industry with no drawbacks like lack of demand per se.Healthcare stocks, especially well-known ones, are no-brainer investments for traders. Their potential is high, and over the long term, their returns are multiplefold.With this in mind, Finbold picked out three healthcare stocks for investors to purchase and hold forever. Johnson & Johnson (NYSE ...

Sales Performance - Total net sales increased by 5.1% excluding foreign exchange impact, driven by growth in Medical Devices and Established Pharmaceuticals, partially offset by a decline in COVID-19 testing sales[90] - COVID-19 testing-related sales totaled $204 million in Q1 2024, down from $730 million in Q1 2023[90] - Medical Devices sales increased by 15.4% excluding foreign exchange, led by double-digit growth in Diabetes Care, Electrophysiology, Vascular, Structural Heart, and Neuromodulation[98] - FreeStyle Libre sales reached $1.5 billion in Q1 2024, a 23.3% increase excluding foreign exchange[98] - Diagnostic Products sales decreased by 15.5% excluding foreign exchange, primarily due to lower demand for COVID-19 tests[96] - Rapid Diagnostics sales declined by 38.7% excluding foreign exchange, driven by reduced COVID-19 testing demand[96] - Nutritional Products sales increased by 7.7% excluding foreign exchange, with U.S. Pediatric Nutritionals up 12.0%[96] - Core Laboratory Diagnostics sales grew by 5.9% excluding foreign exchange, supported by the Alinity testing platform[97] Expenses and Investments - R&D expenses increased by $30 million (4.5%) in Q1 2024 compared to the prior year[100] - SG&A expenses increased by $197 million (7.1%) in Q1 2024, driven by higher spending to support business growth[101] - Abbott completed the acquisition of CSI for $851 million, adding complementary technologies to its vascular device offerings[113] - The final allocation of the CSI acquisition included $305 million in non-deductible developed technology intangible assets and $369 million in non-deductible goodwill[114] Financial Position and Cash Flow - Abbott's cash and cash equivalents decreased from $6.9 billion at December 31, 2023 to $6.3 billion at March 31, 2024, primarily due to dividend payments and capital expenditures[109] - Net cash from operating activities for the first three months of 2024 totaled approximately $1.0 billion, a decrease of $118 million from the prior year[110] - Abbott's working capital decreased from $8.8 billion at December 31, 2023 to $8.4 billion at March 31, 2024, primarily due to a decrease in cash and cash equivalents and an increase in the current portion of long-term debt[109] - Abbott declared a quarterly dividend of $0.55 per share in Q1 2024, representing a 7.8% increase over the $0.51 per share dividend declared in Q1 2023[111] - Abbott has unused lines of credit that provide the ability to borrow up to $5 billion on an unsecured basis[111] Tax and Regulatory Matters - Abbott received a Statutory Notice of Deficiency (SNOD) from the IRS for the 2019 Federal tax year in the amount of $417 million, primarily related to income reallocation between U.S. entities and foreign affiliates[106] - The OECD's Pillar 2 proposal, which includes a 15% minimum tax on multinational corporations' earnings, may have a material impact on Abbott's financial statements in the future[108] Credit Ratings - Abbott's long-term debt rating was AA- by S&P Global Ratings and Aa3 by Moody's Investors Service as of March 31, 2024[110]

Healthcare stocks certainly haven’t set the world on fire lately. The S&P Health Care Index is up 3% so far in 2024 compared to an 8% gain in the benchmark S&P 500. Yet, many leading healthcare companies just issued better-than-expected financial results for this year’s first quarter.Additionally, these stocks tend to perform well during presidential election years. Why? Healthcare is often an issue for candidates on the campaign trail.Many analysts expect healthcare stocks to outperform going forward, espe ...

Abbott (ABT) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Over the past month, shares of this maker of infant formula, medical devices and drugs have returned -5.4%, compared to the Zacks S&P 500 composite's -4.1% change. During this period, the Zacks Medical - Products industry, which Abbott falls in, has lost 3.6%. The key question now is: What could be the stock's future d ...

Investors looking for stocks in the Medical - Products sector might want to consider either Prestige Consumer Healthcare (PBH) or Abbott (ABT) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revi ...

More than 20 million people in the U.S. are living with peripheral artery disease (PAD) yet there have been limited treatment options The first-of-its-kind Esprit™ BTK Everolimus Eluting Resorbable Scaffold dissolves over time after it has opened blocked arteries below the knee (BTK) The Esprit BTK System is a dissolving stent that offers the possibility of better outcomes for people with the most severe form of PAD ABBOTT PARK, Ill., April 29, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that ...

An exhibit from Abbott is seen at the Las Vegas Convention Center during the Consumer Electronics ... [+] Show January 10, 2024, in Las Vegas, Nevada. (Photo by Brendan Smialowski / AFP) (Photo by BRENDAN SMIALOWSKI/AFP via Getty Images)AFP via Getty ImagesAbbott (NYSE: ABT) recently reported its Q1 results, with revenues above and earnings exceeding our expectations. The company reported revenue of $10 billion and earnings of $0.98 on a per-share and adjusted basis, compared to our estimates of $9.9 billio ...

Key TakeawaysAbbott Laboratories stock fell in intraday trading Wednesday as investors reacted to a first-quarter earnings report that beat expectations, but included current-quarter adjusted earnings per share (EPS) guidance mostly below estimates.Lower demand for COVID testing dragged down sales in Abbott's diagnostics division by 17.6% compared to the prior-year quarter.Medical devices posted a 14.2% sales increase from Q1 2023, the biggest percentage gain among company units. Shares of Abbott Laboratori ...

Abbott Laboratories (NYSE:ABT) Q1 2024 Results Conference Call April 17, 2024 9:00 AM ET Company Participants Mike Comilla - Vice President, Investor Relations Robert Ford - Chairman and Chief Executive Officer Phil Boudreau - Senior Vice President, Finance and Chief Financial Officer Bob Funck - Executive Vice President, Finance Conference Call Participants Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Josh Jennings - Cowen Travis Steed - BofA Securities Vijay Kumar - Evercore, ISI Joanne Wuensch ...